You are here

  • Home
  • Archive
  • Volume 73, Issue 1
  • A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

Citation Tools

Article menu
Basic and translational research
Extended report
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Higgs BW, Zhu W, Morehouse C, et al
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
Annals of the Rheumatic Diseases 2014;73:256-262.